Subversive Capital

Subversive Capital explicitly links investing to regulatory and government strategy. It operates four distinct investment lines: venture capital, public-market investing, exchange-traded funds, and whistleblower financing. The whistleblower-financing practice funds litigation for individuals exposing wrongdoing, creating a proprietary sourcing and intelligence advantage that conventional venture firms do not possess.

No. The firm does not publicly name its portfolio companies, fund sizes, or performance metrics on its website or in available regulatory filings as of mid-2026. Allocations are understood to span venture-stage companies and public-market positions, but specific holdings are not disclosed.

Subversive Capital lists whistleblower financing as a distinct investment line, which typically involves funding legal actions brought by individuals who report corporate or government misconduct, in exchange for a share of any financial recovery or settlement. The practice creates a direct link between the firm's capital and the regulatory enforcement landscape.

Yes. Subversive Capital operates an ETF platform that provides thematic exposure aligned with the firm's broader thesis of investing in radical, status-quo-defying ideas. The ETFs serve as a public-market vehicle for the same disruptive themes the firm pursues in private venture investing.

Subversive Capital does not publicly name its founders, managing partners, or investment committee members on its website. No regulatory filings or press releases identifying key principals were available at the time of this research. The firm's leadership and governance structure remain effectively undisclosed.